Pulse Biosciences Files Routine 8-K on Jan 2, 2024
Ticker: PLSE · Form: 8-K · Filed: Jan 2, 2024 · CIK: 1625101
| Field | Detail |
|---|---|
| Company | Pulse Biosciences, Inc. (PLSE) |
| Form Type | 8-K |
| Filed Date | Jan 2, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, compliance, 8-K
TL;DR
**PLSE filed a routine 8-K, no major news.**
AI Summary
Pulse Biosciences, Inc. filed an 8-K on January 2, 2024, to report an "Other Event" and provide financial statements and exhibits. This filing, under the Securities Exchange Act of 1934, confirms the company's current status and its common stock, with a $0.001 par value per share, is traded on The Nasdaq Stock Market under the symbol PLSE. This matters to investors as it's a routine compliance filing, indicating the company is adhering to SEC regulations, which is a positive sign for operational transparency and stability.
Why It Matters
This is a standard compliance filing, indicating Pulse Biosciences is meeting its regulatory obligations. It provides no new material financial or operational information but confirms the company's active status.
Risk Assessment
Risk Level: low — This 8-K is a standard regulatory filing and does not introduce new risks or significant changes to the company's operations or financial health.
Analyst Insight
A smart investor would note this as a routine compliance filing, indicating no immediate need for action. It's a confirmation of ongoing regulatory adherence rather than a signal for buying or selling.
Key Numbers
- $0.001 — par value per share (the stated par value of Pulse Biosciences' common stock)
Key Players & Entities
- Pulse Biosciences, Inc. (company) — the registrant filing the 8-K
- The Nasdaq Stock Market (company) — the exchange where Pulse Biosciences' common stock is registered
- $0.001 (dollar_amount) — par value per share of common stock
- January 2, 2024 (date) — date of earliest event reported and filing date
FAQ
What is the purpose of this 8-K filing by Pulse Biosciences, Inc.?
This 8-K filing, dated January 2, 2024, is a 'Current Report' pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934, reporting 'Other Events' and including 'Financial Statements and Exhibits'.
On which stock exchange is Pulse Biosciences, Inc.'s common stock traded?
Pulse Biosciences, Inc.'s common stock, with a $0.001 par value per share, is registered on The Nasdaq Stock Market under the trading symbol PLSE.
What is the earliest event reported date in this 8-K filing?
The Date of Report (Date of Earliest Event Reported) for this 8-K filing is January 2, 2024.
What is the address of Pulse Biosciences, Inc.'s principal executive offices?
The address of Pulse Biosciences, Inc.'s principal executive offices is 3957 Point Eden Way, Hayward, California, 94545.
What is the Commission File Number for Pulse Biosciences, Inc.?
The Commission File Number for Pulse Biosciences, Inc. is 001-37744.
Filing Stats: 496 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-01-02 09:20:23
Key Financial Figures
- $0.001 — nge on Which Registered Common stock , $0.001 par value per share PLSE The Na
Filing Documents
- plse20231231_8k.htm (8-K) — 24KB
- ex_611054.htm (EX-99.1) — 13KB
- 0001437749-24-000113.txt ( ) — 170KB
- plse-20240102.xsd (EX-101.SCH) — 3KB
- plse-20240102_def.xml (EX-101.DEF) — 11KB
- plse-20240102_lab.xml (EX-101.LAB) — 15KB
- plse-20240102_pre.xml (EX-101.PRE) — 11KB
- plse20231231_8k_htm.xml (XML) — 2KB
01
Item 8.01 Other Events.   On January 2, 2024, Pulse Biosciences, Inc. (the "Company") issued a press release announcing the filing of a premarket notification 510(k) to the U.S. Food and Drug Administration for its novel CellFX nsPFA Cardiac Clamp. A copy of the Company's press release is attached as Exhibit 99.1.  
Financial Statements and Exhibits
Financial Statements and Exhibits.   (d) Exhibits   Exhibit Number Description     99.1 Press Release issued by Pulse Biosciences, Inc. dated January 2, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)         SIGNATURE   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.     PULSE BIOSCIENCES, INC.               Date: January 2, 2024 By: /s/ Kevin P. Danahy       Kevin P. Danahy       President and Chief Executive Officer (Principal Executive and Principal Financial Officer)